Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS) : a randomised, double-blind, phase 3 study

Autor: Chanan-Khan, Asher, Cramer, Paula, Demirkan, Fatih, Fraser, Graeme, Silva, Rodrigo Santucci, Grosicki, Sebastian, Pristupa, Aleksander, Janssens, Ann, Mayer, Jiri, Bartlett, Nancy L, Dilhuydy, Marie-Sarah, Pylypenko, Halyna, Loscertales, Javier, Avigdor, Abraham, Rule, Simon, Villa, Diego, Samoilova, Olga, Panagiotidis, Panagiots, Goy, Andre, Mato, Anthony, Pavlovsky, Miguel A, Karlsson, Claes, Mahler, Michelle, Salman, Mariya, Sun, Steven, Phelps, Charles, Balasubramanian, Sriram, Howes, Angela, Hallek, Michael, Assouline, S, Bence-Bruckler, I, Buckstein, R, Fraser, G, Larratt, L, Minuk, L, Villa, D, Angevine, A, Bartlett, N, Bixby, D, Caimi, P, Chanan-Khan, A, Craig, M, Forero-Torres, A, Ganguly, S, Goy, A, Heffner, L, Hermann, R, Lansigan, F, Leis, J, Letzer, J, Link, B, Liu, D, McCaul, K, McGuire, E, Skinner, W, Starodub, A, Stuart, R, Thirman, M, Tirumali, N, Yang, J, Janssens, A, Offner, F, Van den Neste, E, Van Hoof, A, Mayer, J, Novak, J, Trneny, M, Cartron, G, Dartigeas, C, Dilhuydy, M, Ghez, D, Haioun, C, Leblond, V, Salles, G, Balser, C, Cramer, P, Dreger, P, Durig, J, Eckart, M, Heinrich, B, Illmer, T, Jentsch-Ullrich, K, Pfreundschuh, M, Schetelig, J, Schlag, R, Soling, U, Stilgenbauer, S, Anagnostopoulos, A, Dimopoulos, A, Panagiotidis, P, Vrakidou, E, Bairey, O, Yehuda, D Ben, Braester, A, Fineman, R, Herishanu, Y, Nagler, A, Ruchlemer, R, Tadmor, T, Grosicki, S, Homenda, W, Jurczak, W, Pluta, A, Woszczyk, D, Espirito Santo, A, Luis, R, Raposo, J, Viveiros, C, Alexeeva, J, Dunaev, Y, Golubeva, M, Khuageva, N, Loginov, A, Lysenko, I, Osmanov, E, Pavlov, V, Pristupa, A, Proydakov, A, Rossiev, V, Samarina, I, Samoilova, O, Serduk, O, Shneider, T, Udovitsa, D, Voloshin, S, Gayoso, J, Gonzalez, M, Gonzalez Barca, E, Hernandez Rivas, J, Jargue, I, Loscertales, J, Karlsson, C, Sender, M, Aktan, M, Arslan, O, Demirkan, F, Ferhanoglu, B, Kaynar, L, Sayinalp, N, Vaural, F, Yagci, M, Dyagil, I, Kaplan, P, Masliak, Z, Oliynyk, H, Popovska, T, Pylypenko, H, Rekhtman, G, Dearden, C, Morley, N, Moss, P, Rule, S, Pavlovsky, M, Riveros, D, Santucci-Silva, R, Romeo, M, Scheliga, A, Salazar, L, Gomez, D, Ramirez, E, Jung, C

Most patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma relapse after initial therapy. Bendamustine plus rituximab is often used in the relapsed or refractory setting. We assessed the efficacy and safety of adding ibrutinib, an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afe583710bcd15b107e94325ade65998
https://www.ncbi.nlm.nih.gov/pubmed/26655421

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Prognosis factors in imatinib mesilate therapy in patients with a chronic phase of PH-positive chronic myeloid leukemia: Data from a multicenter non-randomized trial in Russia

Autor: Zaritsky, A. Yu, Lomaia, E. G., O.Yu. Vinogradova, Druzhkova, G. A., Kolosheinova, T. I., Loria, S. S., Pospelova, T. I., Krylova, I. V., Kruglov, S. S., Kuznetsov, S. V., Chelysheva, E. Yu, Abakumov, E. M., Sokolova, M. A., Nemchenko, I. S., Zakharova, E. S., Goryacheva, S. R., Kolosova, L. Yu, Vakhrusheva, M. V., Lyamkina, A. S., Chemova, O. A., Machulaitene, E. R., Ivanova, V. L., Udatyeva, V. Yu, Shneider, T. V., Ogorodnikova, Yu S., Zhuravlev, V. S., Zakharova, A. V., Martynkevich, I. S., Domracheva, E. V., Afanasyev, B. V., Abdulkadyrov, K. M., Kovaleva, L. G., Khoroshko, N. D., Turkina, A. G.

Publikováno v: Scopus-Elsevier

To reveal prognostically significant factors affecting efficacy of glivek therapy in untreated (duration of the diseaseor = 6 months) and pretreated (duration of the disease6 months) patients with chronic myeloid leukemia (CML) in a chronic phase.A t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::dca16147ca1eeda3e99402f03f1c0dbd
http://www.scopus.com/inward/record.url?eid=2-s2.0-35148821453&partnerID=MN8TOARS

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.